Integra LifeSciences Holdings Corporation — FY2016 Form 10-K Summary
Business context and reporting period
Integra is a global medical technology company serving neurosurgery, specialty surgical, regenerative technology, wound care, extremity orthopedics and related markets. Its two reportable segments are Specialty Surgical Solutions and Orthopedics and Tissue Technologies. This Form 10-K covers the fiscal year ended December 31, 2016 and was filed February 23, 2017. Results are presented primarily from continuing operations following the July 2015 tax-free separation of SeaSpine.
Integra had approximately 3,700 employees at year-end. The company completed a two-for-one stock split effective January 3, 2017; share and per-share data in the filing have generally been adjusted retroactively.
Key financial metrics
| Metric | 2016 | 2015 | Change |
|---|---|---|---|
| Revenue | $992.1 million | $882.7 million | Up 12% |
| Gross margin | $643.0 million | $556.2 million | Up 15.6% |
| Gross margin percentage | 64.8% | 63.0% | Up 180 basis points |
| Operating income | $115.3 million | $79.6 million | Up 45% |
| Income from continuing operations | $74.6 million | $6.9 million | Material increase |
| Diluted EPS from continuing operations | $0.94 | $0.10 | Material increase |
| Net income | $74.6 million | $(3.5) million | Returned to profitability |
| Net cash from operating activities | $116.4 million | $117.1 million | Down slightly |
| Capital expenditures | $47.3 million | $33.4 million | Up $13.9 million |
Specialty Surgical Solutions revenue was $632.5 million, up 8%. Orthopedics and Tissue Technologies revenue was $359.6 million, up 22%, supported substantially by the full-year contribution of the 2015 TEI and Salto/Futura acquisitions. U.S. revenue was $765.6 million, or approximately 77% of total revenue; international revenue was $226.5 million. Foreign exchange reduced 2016 revenue by approximately $2.7 million.
Research and development expense was $58.2 million, or 5.9% of revenue. Selling, general and administrative expense was $455.6 million, or 45.9% of revenue. Interest expense was $25.8 million. The effective tax rate was 17.5%, compared with 88.7% in 2015, primarily because 2015 included a $37.2 million valuation allowance related to the SeaSpine separation and 2016 benefited from share-based compensation tax accounting changes.
Financial position, debt and liquidity
| Balance-sheet item | December 31, 2016 | December 31, 2015 |
|---|---|---|
| Cash and cash equivalents | $102.1 million | $48.1 million |
| Total assets | $1.808 billion | $1.774 billion |
| Working capital | $371.6 million | $299.4 million |
| Total senior credit facility borrowings | $665.0 million | $496.3 million |
| Stockholders’ equity | $839.7 million | $751.4 million |
On December 7, 2016, Integra amended and restated its senior credit facility, increasing total commitments to $1.5 billion, consisting of a $1.0 billion revolver and a $500.0 million term loan, and extending maturity to December 7, 2021. Approximately $835.0 million remained available at year-end. No debt matured in 2017, and term-loan principal repayments begin in March 2018. The company was in compliance with its financial covenants.
The $1.625% convertible notes were settled in December 2016. Integra paid $227.1 million of principal, issued approximately 2.9 million shares for excess conversion value and received approximately 2.9 million shares through related hedge transactions, which were held as treasury stock. The company has not paid cash dividends and had $150.0 million remaining under its share repurchase authorization, although no repurchases occurred in 2016 or 2015.
Material changes versus the prior comparable period
- Revenue increased 12%, with particularly strong growth in Orthopedics and Tissue Technologies and improved product mix.
- Gross margin expanded to 64.8%, helped by higher-margin DuraSeal, DuraGen, skin and wound products, private-label royalties, manufacturing leverage and TEI products.
- Operating income increased to $115.3 million despite higher selling and marketing costs and continued product-development investment.
- Net income benefited substantially from the absence of the 2015 SeaSpine-related tax valuation allowance.
- Operating cash flow remained broadly stable because 2016 included approximately $42.8 million of accreted-interest payments associated with the convertible-note settlement.
- Special charges declined to $51.8 million from $63.1 million, primarily due to lower structural optimization, employee termination and spin-off costs, partly offset by higher acquisition-related charges.
- Integra adopted ASU 2016-09 early, recognizing $3.8 million of excess tax benefits in income-tax expense and increasing reported operating cash flow by $8.8 million for 2016.
Guidance, outlook, commentary and unusual items
- Management expected 2017 gross margin of approximately 65% to 66%, research and development expense of approximately 6.0% of revenue, selling, general and administrative expense of approximately 51% to 52% of revenue, and an effective tax rate of approximately 20% to 22%.
- Management expected 2017 capital expenditures of approximately $50 million to $55 million, primarily for plant support and automation and orthopedic instrument kits.
- ERP implementation and facility optimization were substantially advanced; management expected related capital and integration expenses to decrease in 2017, while benefits from restructuring and manufacturing transfers remained uncertain.
- Integra received FDA PMA approval for Omnigraft for diabetic foot ulcers in January 2016 and began commercialization late in 2016. It also submitted DuraSeal post-approval study results to the FDA in October 2016.
- Subsequent to year-end, Integra agreed to acquire Derma Sciences for approximately $207.6 million and submitted a binding offer to acquire Johnson & Johnson’s Codman Neurosurgery business for approximately $1.0 billion, subject to adjustments, financing and closing conditions.
- Three shareholder lawsuits challenged the proposed Derma Sciences acquisition. Plaintiffs agreed not to pursue preliminary injunctive relief in exchange for additional disclosures; the filing states that the outcome remained uncertain.
Principal risks and contingencies
- Medical-device regulatory risk, including an outstanding FDA warning letter relating to TEI’s historical promotion of SurgiMend for an unapproved breast-surgery indication.
- Product-liability exposure involving approximately 50 active cases against TEI related to a bovine-derived surgical mesh product. Insurance and indemnification protections exist but may not cover all losses.
- Approximately 41% of 2016 revenue was attributable to products containing bovine-derived material, creating potential sourcing, regulatory and market-acceptance risks.
- High acquisition activity creates integration, financing, amortization, goodwill impairment, contingent consideration and execution risks. Goodwill was $510.6 million and finite-lived intangible assets were $560.2 million at year-end.
- Debt and interest-rate exposure increased following the 2016 refinancing. A one-percentage-point change in rates was estimated to affect annual interest expense on unhedged debt by approximately $5.2 million.
- Foreign exchange, reimbursement reductions, healthcare cost controls, hospital purchasing consolidation, competition, sole-source suppliers, manufacturing disruptions and cybersecurity incidents could adversely affect results.
- Pending Codman and Derma transactions could require significant additional borrowing and integration resources; failure to close either transaction could result in costs, termination fees or adverse market reaction.
Most important facts for an investor to verify
- Whether the projected 2017 margin improvement and cost leverage materialized after incorporating the Derma Sciences and Codman Neurosurgery transactions.
- The final purchase price, financing structure, leverage and covenant headroom associated with the Codman Neurosurgery acquisition.
- The closing status and integration performance of the Derma Sciences acquisition, including resolution of related litigation.
- Progress and final disposition of the TEI FDA warning-letter remediation and product-liability matters.
- Organic revenue growth excluding acquisitions, particularly within regenerative technologies and Orthopedics and Tissue Technologies.
- Cash conversion after capital expenditures, acquisition spending, debt service and any required working-capital investment.
- Potential goodwill or intangible-asset impairment, especially if acquired businesses underperform management projections.
- The effect of reimbursement changes, currency movements and the scheduled potential reinstatement of the U.S. medical-device excise tax after 2017.